ArticleFrontiers in nutrition2026
Role of enteral nutrition in the clinical care, management, and quality of life of patients with inflammatory bowel disease.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enteral nutrition (EN) is essential for Inflammatory Bowel Disease treatment. This applies mainly to Crohn's disease (CD) and ulcerative colitis (UC) patients. The study evaluated the impact of EN treatment on clinical, nutritional, inflammatory, and quality of life outcomes in IBD patients. This study aimed to examine the association between EN therapy's clinical, nutritional, inflammatory, and Quality of Life (QoL) effects on Inflammatory Bowel Disease patients. Methods: A retrospective study investigated 750 Chinese IBD patients. These patients had 400 CD and 350 UC diagnoses. Medical records provided data. EN formula, administration, calorie density, and duration were studied along with disease activity, nutritional markers including hemoglobin, albumin, and body mass index, and inflammatory indices like erythrocyte sedimentation rate. Validated IBDQ measures quality of life. Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score < 150 for CD patients and a Mayo score ≤ 2 (with no individual subscore > 1) for UC patients, assessed after completion of EN therapy. Chi-square and Results: Baseline characteristics of 750 patients are comparable between groups. Elemental and semi-elemental formulas were more frequently prescribed in CD patients and were associated with higher caloric and protein intake ( Conclusion: EN therapy corresponded with clinical remission, improved nutritional markers, and reduced inflammation in IBD patients, particularly those with CD. These findings support the potential role of EN as a complementary strategy in IBD management; however, prospective randomized trials are further confirming these associations and standardize therapeutic protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.